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Pardiovascular Morbidity and Mortality in
ypertensive Patients With a History of Atrial Fibrillation
he Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study
ristian Wachtell, MD, PHD,*† Björn Hornestam, MD, PHD,‡ Mika Lehto, MD,§
avid J. Slotwiner, MD, FACC,† Eva Gerdts, MD, PHD, Michael H. Olsen, MD, PHD,*
eter Aurup, MD,¶ Björn Dahlöf, MD, PHD, FACC,‡ Hans Ibsen, MD,* Stevo Julius, MD, FACC,#
verre E. Kjeldsen, MD, PHD, FACC,** Lars H. Lindholm, MD,†† Markku S. Nieminen, MD,§
ens Rokkedal, MD,* Richard B. Devereux, MD, FACC†
lostrup, Denmark; New York, New York; Göteborg and Umeå, Sweden; Helsinki, Finland; Bergen and Oslo,
orway; West Point, Pennsylvania; and Ann Arbor, Michigan
OBJECTIVES We assessed the impact of antihypertensive treatment in hypertensive patients with electrocar-
diographic (ECG) left ventricular (LV) hypertrophy and a history of atrial fibrillation (AF).
BACKGROUND Optimal treatment of hypertensive patients with AF to reduce the risk of cardiovascular
morbidity and mortality remains unclear.
METHODS As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study,
342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or
atenolol-based therapy for 1,471 patient-years of follow-up.
RESULTS The primary composite end point (cardiovascular mortality, stroke, and myocardial infarc-
tion) occurred in 36 patients in the losartan group versus 67 in the atenolol group (hazard
ratio [HR]  0.58, 95% confidence interval [CI] 0.39 to 0.88, p  0.009). Cardiovascular
deaths occurred in 20 versus 38 patients in the losartan and atenolol groups, respectively (HR
 0.58, 95% CI 0.33 to 0.99, p  0.048). Stroke occurred in 18 versus 38 patients (HR 
0.55, 95% CI 0.31 to 0.97, p  0.039), and myocardial infarction in 11 versus 8 patients (p
 NS). Losartan-based treatment led to trends toward lower all-cause mortality (30 vs. 49,
HR  0.67, 95% CI 0.42 to 1.06, p  0.090) and fewer pacemaker implantations (5 vs. 15,
p  0.065), whereas hospitalization for heart failure took place in 15 versus 26 patients and
sudden cardiac death in 9 versus 17, respectively (both p  NS). The benefit of losartan was
greater in patients with AF than those with sinus rhythm for the primary composite end point
(p  0.019) and cardiovascular mortality (p  0.039).
CONCLUSIONS Losartan is more effective than atenolol-based therapy in reducing the risk of the primary
composite end point of cardiovascular morbidity and mortality as well as stroke and cardiovascular
death in hypertensive patients with ECG LV hypertrophy and AF. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.08045:705–11) © 2005 by the American College of Cardiology Foundation
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ttrial fibrillation and flutter (AF) increase the risk of
ardiovascular morbidity and mortality (1,2), and hyperten-
See page 720
ive patients have up to a 42% increased risk of developing
F (1,3). Because many hypertensive patients develop AF,
he addition of AF to hypertension contributes to increased
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ccepted June 9, 2004.ates of cardiovascular morbidity and mortality in hyperten-
ion. Traditionally, restoration of sinus rhythm by direct
urrent conversion has been attempted in patients with AF
4), although this treatment remains controversial. A recent
tudy showed that management of AF with a rhythm-
ontrol strategy offered no survival advantage over the
ate-control strategy (5). Therefore, combined use of
igoxin and either beta-blockers or calcium antagonists to
reat hypertension and achieve rate control may be increas-
ngly preferred by clinicians (4). However, no data are
vailable to determine whether traditional beta-blocker–
ased therapy or direct inhibition of the renin-angiotensin
ystem reduces cardiovascular mortality and morbidity more
n hypertensive patients with AF. As previously described
6–8), the Losartan Intervention For End point reduction
n hypertension (LIFE) study primary hypothesis was that
elective angiotensin-II type 1 receptor blockade with losar-
an would be more effective than beta-blockade with atenolol
n reducing cardiovascular morbidity and mortality in hyper-
ensive patients with electrocardiographic (ECG) left ventric-
lar (LV) hypertrophy. Therefore, we analyzed the outcome in
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Treatment of LV Hypertrophy and AF March 1, 2005:705–11he subgroup of hypertensive patients with ECG LV hyper-
rophy (n  342) who had a history of AF or electrocardio-
raphically verified AF at the start of the LIFE study to
valuate the treatment effect of a specific angiotensin-II recep-
or versus beta-blockade on cardiovascular morbidity and
ortality in hypertensive patients with ECG LV hypertrophy.
ETHODS
tudy population. The LIFE study was a prospective,
andomized, double-blind, parallel-group study with a
ouble-dummy technique. The primary objective and main
utcome, as well as the complete study protocol with study
esign, organization, clinical measures, end point defini-
ions, exclusion criteria, basis for choice of comparative
gents, statistical considerations, and baseline characteris-
ics, have been previously published (6–8).
Patients age 55 to 80 years, having previously treated or
ntreated hypertension and ECG LV hypertrophy by either
ornell voltage-duration or Sokolow-Lyon voltage criteria
9), were randomized to initial therapy with 50 mg/day
osartan or atenolol after one to two weeks of placebo if they
ad a sitting systolic blood pressure of 160 to 200 mm Hg
nd/or diastolic blood pressure of 95 to 115 mm Hg. In
oth groups, hydrochlorothiazide was added in the case of
nsufficient pressure lowering. Thereafter the study drug was
ncreased to 100 mg/day and supplemented with additional
ntihypertensive therapy in order to reach a target blood
ressure of 140/90 mm Hg. Patients were enrolled from
une 1995 to May 1997 and were followed for four years or
onger. Of 342 LIFE study participants (3.7% of 9,193) who
ad either electrocardiographically documented AF or a
istory of AF (n  324) or atrial flutter (n  18) reported
y the investigator at baseline, 157 were randomized to
osartan and 185 to atenolol. Centralized ECG reading
onfirmed that 135 patients (40%) had persistent or perma-
ent AF documented by electrocardiography. The care of
atients’ AF was left to the discretion of the physician.
tatistical analysis. All end points were analyzed using the
ntention-to-treat approach, all randomized patients were
ncluded in their randomized treatment group, and all
vailable follow-up data were included from randomization
hrough the study termination date. Only end points con-
rmed by the Endpoint Committee were included in
nalyses. Patients with multiple end points were counted as
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
ECG  electrocardiographic
HF  heart failure
HR  hazard ratio
LIFE  Losartan Intervention For End point reduction
in hypertension study
LV  left ventricular
MI  myocardial infarctionaving had an event in all relevant end point analyses; cowever, only the first event in a specific category counted
n any individual analysis. The difference between treatment
roups with respect to clinical events was assessed by Cox
egression models with the degree of LV hypertrophy (as
easured by both Cornell voltage-duration product and
okolow-Lyon voltage) and the Framingham risk score (10)
t baseline and difference in blood pressure during treatment
s covariates. This adjusted analysis was chosen a priori
rimarily to account for any difference in key risk predictors
t baseline; additional adjustments based on findings in the
resent study are described. The risk reduction for losartan
ersus atenolol was calculated as: 100·(1  relative risk).
vent rates over time are presented as Kaplan-Meier curves:
he numbers below the curves represent the number of
vent-free patients remaining in follow-up at the corre-
ponding time point. Differences in baseline characteristics
ere assessed by Student t test and chi-square for categor-
cal variables. Tests were performed at two-sided 5% sig-
ificance levels. For further details, see Dahlöf et al. (8).
ESULTS
istory of AF versus sinus rhythm. Demographic char-
cteristics of patients with or without a history of AF at
nrollment in the LIFE study are compared in Table 1.
eart rate was similar at baseline and during treatment in
atients with a history of AF compared with patients in
inus rhythm (p  NS).
Patients with a history of AF had, compared with those
ithout, higher rates of cardiovascular and all-cause mor-
ality, fatal and non-fatal stroke, heart failure (HF), revas-
ularization, and sudden cardiac death, but statistically
imilar rates of myocardial infarction (MI) and hospitaliza-
ion for angina pectoris (Table 2).
reatment of patients with a history of AF. Patients with
history of AF assigned to losartan- or atenolol-based
reatment had comparable demographic characteristics (Ta-
le 1). During the study medications were titrated similarly
n the two treatment arms. At end point or termination of
ollow-up 8.3% and 11.4% of losartan- and atenolol-treated
atients, respectively, received 50 mg of study drug alone;
2.7% and 14.5%, respectively, received 50 mg of study drug
lus hydrochlorothiazide or other medications; and 43% and
1%, respectively, received 100 mg of the study drug with or
ithout hydrochlorothiazide or additional medications.
urthermore, hydrochlorothiazide was administered in 61%
f study duration in losartan-treated and 52% of study
uration in atenolol-treated patients (p  NS).
Patients with a history of AF had a similar high preva-
ence of use of another antihypertensive therapy (e.g.,
entrally acting and/or non-dihydropyridine calcium chan-
el blocker) and received similar concomitant treatment
ith other rate-controlling, antiarrhythmic and lipid-
owering drugs during the study (Table 3). Most patients
dhered to the treatment regimen, and crossover treatment
ccurred mainly in patients who discontinued study medi-
ation. Among patients originally assigned to losartan,
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March 1, 2005:705–11 Treatment of LV Hypertrophy and AF7.6% crossed over to beta-blockade, and among those
riginally assigned to atenolol, 34.9% crossed over to
ngiotensin-converting enzyme inhibition/angiotensin-II
eceptor blockade by the study’s end. Patients who discon-
inued losartan were no more likely to receive open-label
eta-blockade than patients who discontinued atenolol
27.6% vs. 31.7%, p  NS). Open-label combination
herapy of beta-blocker and angiotensin-converting enzyme
nhibition/angiotensin-II receptor blockade during the
tudy was seen in 14.6% and 21.6%, respectively, among
osartan- and atenolol-assigned patients (p  0.123).
able 1. Characteristics of Losartan- and Atenolol-Treated Patie
Characteristic
All Nonatrial
Fibrillation
(n  8,851)
emographic and clinical
Age (yrs) 66.8  7.0
Women, n (%) 4,815 (54.4)
Ethnic origin, n (%)
White 8,179 (96.2)
Black 520 (5.9)
Hispanic 98 (1.1)
Asian 41 (0.5)
Other 13 (0.1)
Blood pressure (mm Hg) 174/98  14/10
Heart rate (beats/min) 74  11
Body mass index (kg/m2) 28.0  4.8
Cornell voltage-duration product (mV·ms) 2,820  1,033
Sokolow-Lyon (mV) 29.9  10.5
Framingham risk score 0.222  0.094
Current smokers, n (%) 1,450 (16.4)
Current atrial fibrillation, n (%) —
edical history
Coronary heart disease, n (%) 1,162 (13.1)
Cerebrovascular disease, n (%) 679 (7.7)
Peripheral vascular disease, n (%) 480 (5.4)
Diabetes mellitus, n (%) 1,112 (12.6)
Isolated systolic hypertension, n (%)¶ 1,252 (14.3)
tatistical significance: *compared with patients with vs. without AF; †all NS compare
ressure 90 mm Hg.
able 2. End Points in Patients With and Without Atrial Fibrill
End Point
Atrial Fibrillation
(n  342)
Nonatr
Fibrillat
(n  8,8
Rate† n (%) Rate† n
rimary composite end point 70.0 103 30.1 23.5 993
omponents
Cardiovascular mortality 36.1 58 17.0 8.7 380
Stroke 35.8 56 16.4 11.2 485
Myocardial infraction 11.3 19 5.6 8.4 367
ther prespecified end points
Total mortality 50.2 79 23.1 17.1 735
Hospitalization for
Angina pectoris 7.1 12 3.5 5.6 247
Heart failure 24.1 41 12.0 6.1 265
Revascularization 15.6 26 7.6 4.7 205
Sudden cardiac death‡ 15.5 26 7.6 3.7 164
For degree of left ventricular hypertrophy, Framingham risk score, and treatment allo
rrest, cardiac death within 24 h.
CI  confidence interval.Systolic, diastolic, and mean blood pressures were re-
uced substantially in both losartan- and atenolol-treated
atients (Fig. 1). Average blood pressure at the last visit
efore a primary end point, or at the end of follow-up, was
45/81 and 147/79 mm Hg in the losartan and atenolol
roups, respectively, showing reductions of 31/17 and 26/16
m Hg. The average reduction in heart rate during the first
2 months of treatment was significantly greater in
tenolol-treated patients (9.9 beats/min vs. 3.5 beats/min, p
0.001), but very similar at study end (Fig. 2). There was
trend toward higher serum potassium during treatment in
ith Atrial Fibrillation
All History of AF*
(n  342)
Losartan
(n  157)
Atenolol†
(n  185)
70.3  6.4‡ 69.9  6.7 70.7  6.2
148 (43.3)‡ 64 (41.0) 84 (45.2)
324 (94.7)ns 146 (93.6) 178 (95.7)
13 (3.8) 8 (5.1) 5 (2.7)
2 (0.6) 0 2 (1.1)
2 (0.6) 1 (0.6) 1 (0.5)
1 (0.3) 1 (0.6) 0
176/96  14/10ns/§ 177/97  14/10 175/96  14/10
75  14§ 75  14 76  14
27.4  4.6§ 27.1  4.6 27.6  4.6
3,051  1,392 2,968  1,392 3,120  1,393
32.0  10.6‡ 32.3  11.1 31.8  10.2
0.265  0.103‡ 0.270  0.104 0.262  0.103
49 (14.3)ns 20 (12.8) 29 (15.6)
135 (39.5) 51 (32.5) 64 (34.6)
882 (25.7)‡ 44 (28.2) 44 (23.7)
49 (14.3)‡ 20 (12.8) 29 (15.6)
40 (11.7)‡ 14 (9.0) 26 (14.0)
83 (24.3)‡ 34 (21.8) 49 (26.3)
68 (20.3) 27 (17.6) 41 (22.5)
sartan; ‡p 0.001; §p 0.05; p 0.01; ¶systolic blood pressure160 and diastolic
Adjusted
Hazard Ratio*
p
Value
Unadjusted
Hazard Ratio
p
Value%) 95% CI 95% CI
1.2 2.23 1.81–2.74  0.001 2.95 2.4–3.62  0.001
 0.001
4.3 3.06 2.31–4.06  0.001 4.19 3.18–5.52  0.001
5.5 2.44 1.84–3.25  0.001 3.08 2.33–4.08  0.001
4.1 1.03 0.65–1.64 0.895 1.34 0.85–2.13 0.209
8.3 2.32 1.83–2.93  0.001 2.99 2.37–3.78  0.001
2.8 0.95 2.16–4.24 0.866 1.26 0.7–2.24 0.440
3.0 3.02 1.56–3.59  0.001 4.15 2.99–5.76  0.001
2.3 2.37 1.56–3.59  0.001 3.37 2.24–5.06  0.001
1.9 2.93 1.92–4.48  0.001 4.21 2.78–6.36  0.001
. †Per 1,000 patient-years of follow-up. ‡Composite end point of resuscitated cardiacnts Wation
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Treatment of LV Hypertrophy and AF March 1, 2005:705–11atients with a history of AF compared with those in sinus
hythm (4.21  0.41 mmol/l vs. 4.17  0.39 mmol/l, p 
.06). Among patients with a history of AF there was no
ifference in serum potassium during treatment between
osartan-treated and atenolol-treated groups (4.20  0.43
mol/l vs. 4.22  0.40 mmol/l, p  NS).
linical outcome. Patients with a history of AF on losar-
an treatment had a significantly lower rate of the primary
omposite end point than those treated with atenolol during
,471 patient-years of follow-up (Table 4, Fig. 3). Losartan-
reated patients also had lower rates of cardiovascular death
nd stroke, with no difference in MI rate. The treatment
ffects on hemorrhagic or ischemic stroke were similar (data
ot shown). There was no evidence of interaction between
reatment and gender for any pre-specified end point (all p
0.144). A pacemaker was implanted in 15 (8.1%)
tenolol-treated and 5 (3.2%) losartan-treated patients,
espectively, during the study (p  0.065). Furthermore,
osartan tended to reduce the prevalence of electrocardio-
able 3. Concomitant Drug at Baseline, at End Point, or Termin
Concomitant Treatment
Previous
Treatment
-vitamin antagonist 37 (23.7)
spirin, clopidogrel, dipyridamole, ticlide 3 (1.9)
ther platelet inhibitors 0 (0)
igoxin 82 (52.6)
erapamil 11 (7.1)
iltiazem 9 (5.8)
lass IA antiarrhythmic drug 9 (5.8)
lass IC antiarrhythmic drug 6 (3.8)
lass III antiarrhythmic drug 1 (0.6)
eta-blocker 52 (33.3)
CE inhibitors or angiotensin II receptor blocker 42 (26.9)
ther concomitant antihypertensive agents 38 (24.2)
MG-CoA reductase enzyme inhibitor 10 (6.4)
All NS compared with losartan at baseline. †All NS compared with losartan during
ACE  angiotensin-converting enzyme; HMG-CoA  HMG-coenzyme A.o
igure 1. Systolic, diastolic, and mean arterial blood pressure in hypertensive
atients with atrial fibrillation during follow-up; intention-to-treat analysis.raphically documented AF by 14% at the annual visits
uring the following 4.8 years observation (losartan 50.3%
s. atenolol 55.7%, hazard ratio [HR]  0.86, 95% confi-
ence interval [CI] 0.64 to 1.15, p  0.30).
Comparing patients with or without AF at baseline and
sing tests for interaction in Cox regression models with
ramingham risk score and measures of ECG LV mass as
ovariates, the benefit of losartan was greater in patients
ith a history of AF than in other patients for both the
rimary composite end point (p  0.019 for interaction)
nd for cardiovascular mortality (p  0.039 for interaction).
Alternative adjustment for differences in the prevalence of
eripheral vascular disease, diabetes, and isolated systolic
ypertension instead of Framingham Risk Score yielded
Rs associated with losartan treatment of 0.61 for the
rimary composite end point (95% CI 0.41 to 0.92, p 
.019), 0.64 for cardiovascular mortality (95% CI 0.37 to
.11, p  0.114), 0.52 for stroke (95% CI 0.29 to 0. 92, p
0.024), 1.70 for MI (95% CI 0.68 to 4.28, p  0.260),
nd 0.74 for total mortality (95% CI 0.47 to 1.18, p 
.206). Other secondary end points did not attain statistical
ignificant difference (data not shown).
Among patients with a history of AF but without
linically recognized diabetes or coronary, cerebral, or pe-
ipheral vascular disease at enrollment in the LIFE study,
he composite end point occurred in 10 of 77 patients in the
osartan group versus 22 of 82 in the atenolol group (26.3 vs.
2.8 per 1,000 patient-years; HR  0.57, 95% CI 0.38 to
.87, p  0.008). The secondary end point of stroke
ccurred in 5 versus 17 patients (13.1 vs. 47.1 per 1,000
atient-years) in the losartan and atenolol groups, respec-
ively (HR  0.52, 95% CI 0.29 to 0.92, p  0.025). A
arallel albeit non-significant trend was seen for cardiovas-
ular death (12.8 vs. 25.7 deaths per 1,000 patient-years;
R 0.60, 95% CI 0.35 to 1.03, p 0.06), but not for MI
n of Follow-Up (n  342)
rtan (%)
 157)
Atenolol (%)
(n  185)
By Study End
Previous
Treatment* By Study End†
69 (44.2) 32 (17.2) 80 (43.0)
11 (7.1) 2 (1.1) 12 (6.5)
4 (2.6) 0 (0) 4 (2.2)
89 (57.1) 104 (55.9) 107 (57.5)
10 (6.4) 12 (6.5) 16 (8.6)
14 (9.0) 6 (3.2) 15 (8.1)
12 (7.7) 9 (4.8) 10 (5.4)
6 (3.8) 6 (3.2) 6 (3.2)
7 (4.5) 3 (1.6) 13 (7.0)
42 (27.6)‡ 59 (31.7) 59 (31.7)‡
52 (33.3)‡ 56 (30.1) 65 (34.9)‡
76 (48.4) 45 (24.3) 100 (54.1)
37 (23.7) 16 (8.6) 43 (23.1)
. ‡Either discontinued study and treated open-label or protocol violator.atio
Losa
(nr other secondary end points (data not shown).
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March 1, 2005:705–11 Treatment of LV Hypertrophy and AFISCUSSION
he present study extends knowledge of AF and its treat-
ent in several regards. First, we show that AF is associated
ith increased cardiovascular morbidity and mortality in
ypertensive patients at high risk because of the presence of
V hypertrophy, as previously shown in predominately
ormotensive populations (11). Second, the present results
rovide the first evidence that greater prognostic benefit is
rovided to hypertensive patients with AF by one versus
nother medication with similar blood pressure lowering,
uilding on previous evidence of the benefits of effective
lood pressure control (12–14). The rate of the composite
nd point in the LIFE study, as well as the rates of
ardiovascular mortality and stroke, was significantly lower
ith losartan- compared to atenolol-based therapy, begin-
ing at one year of treatment. Third, the present study is the
rst to suggest that losartan is better than atenolol in
educing recurrence of AF in patients with a history of AF.
iven the frequent occurrence of reduced exercise tolerance
nd increased dyspnea in AF compared with sinus rhythm,
eeping patients in sinus rhythm is often a clinical priority.
Our study did not show reductions of MI and hospital-
zations for angina pectoris or HF with losartan in hyper-
igure 2. Heart rate in hypertensive patients with a history of atrial
brillation treated with losartan and atenolol during follow-up. *p  0.01.
*p  0.001.
able 4. End Points in Losartan- and Atenolol-Treated Patients
End Point
Losartan
(n  157)
Ateno
(n  1
Rate† n (%) Rate† n
rimary composite end point 50.3 36 22.9 88.8 67
omponents
Cardiovascular mortality 26.2 20 12.7 45.2 38
Stroke 24.1 18 11.5 46.5 38
Myocardial infarction 14.2 11 7.0 8.9 8
ther pre-specified end points
Total mortality 40.1 30 19.1 59.4 49
Hospitalization for
Angina pectoris 7.7 6 3.8 6.5 6
Heart failure 19.1 15 9.6 30.1 26
Revascularization 14.2 11 7.0 16.9 15
Sudden cardiac death‡ 11.4 9 5.7 19.3 17
For degree of left ventricular hypertrophy, electrocardiographic atrial fibrillation, F
Composite end point of resuscitated cardiac arrest, cardiac death within 24 h.
CI  confidence interval.ensive patients with a history of AF. However, beta-
lockade is a well-documented treatment for ischemic heart
isease and has shown substantial effect on morbidity and
ortality in patients with angina pectoris, previous MI, and
F. A study of patients with hypertension and HF showed
50% reduction in sudden death and a 30% reduction in
ospitalizations for HF with metoprolol compared with
lacebo treatment (15) on top of standard treatments,
ncluding angiotensin-converting enzyme inhibition. Fur-
hermore, beta-blocker use has been shown to indepen-
ently reduce the risk of pump failure death in patients with
F (16). That treatment with losartan did as well as
tenolol in MI and hospitalization for angina and HF is
eassuring because of the high risk of coronary events in
ypertensive patients with LV hypertrophy.
Another important observation of this study is the fact
hat beta-blocker treatment did not seem to reduce the risk
f sudden cardiac death compared with losartan treatment.
his is surprising, as many regard beta-blocker therapy as a
rst-line intervention for prevention of sudden cardiac
eath (17). In the merged European Myocardial Infarct
miodarone Trial (EMIAT) and Canadian Amiodarone
yocardial Infarction Trial (CAMIAT) databases, con-
omitant use of beta-blockers and amiodarone provided a
urvival benefit, especially for arrhythmic cardiac death (18).
n our study, even though the difference in sudden cardiac
eath did not attain statistical significance, there was a 48%
isk reduction favoring the losartan-treated patients. Fur-
hermore, beta-blocker–treated patients seemed to need
ncreased pacemaker implantation even though patients at
aseline had heart rates averaging 75 beats/min. Losartan
lso reduced heart rate, albeit less than atenolol, with less
eart rate difference at the end of study (Fig. 2). This might
e due to blockade of sympathetic nervous system activation
y renin-angiotensin system blockade by losartan.
echanisms. One explanation for the added effects by
osartan on cardiovascular morbidity and mortality in this
ypertensive population with LV hypertrophy could be the
Atrial Fibrillation
Adjusted
Hazard Ratio*
p
Value
Unadjusted
Hazard Ratio
p
Value%) 95% CI 95% CI
6.2 0.58 0.39–0.88 0.009 0.58 0.39–0.87 0.009
0.5 0.58 0.33–0.99 0.048 0.58 0.33–0.99 0.045
0.5 0.55 0.31–0.97 0.039 0.55 0.31–0.97 0.038
4.3 1.49 0.60–3.72 0.392 1.63 0.65–4.04 0.296
6.5 0.67 0.43–1.06 0.090 0.67 0.42–1.05 0.079
3.2 1.18 0.38–3.69 0.778 0.65 0.34–1.22 0.182
4.1 0.66 0.35–1.25 0.206 1.14 0.37–3.53 0.824
8.1 0.82 0.38–1.79 0.615 0.83 0.38–1.82 0.647
9.2 0.57 0.25–1.29 0.179 0.59 0.26–1.33 0.204
gham Risk Score, and treatment allocation. †Per 1,000 patient-years of follow-up.With
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Treatment of LV Hypertrophy and AF March 1, 2005:705–11arallel effects of losartan on regression of atrial and ven-
ricular hypertrophy. We have recently shown in the LIFE
chocardiography substudy that patients with LV hypertrophy
lso exhibit increased left atrial size and hypertrophy (19),
hich have been associated with increased risk of stroke in
opulation of normotensive and hypertensive adults (20).
urther analyses from the LIFE echocardiography study will
nvestigate whether left atrial diameter decreases with reduc-
ion in LV mass during treatment and whether this is related
o a reduction in subsequent events.
Another possible explanation for reduced vascular events
ith losartan treatment could be greater effects on arterial
therothrombosis or on coagulation system activation in pa-
igure 3. Kaplan-Meier curves in each treatment group of hypertensive
omposite end point; (B) cardiovascular death; (C) fatal or non-fatal myoients with AF. However, the fact that the benefit of losartan aas not limited to high-risk patients with either vascular
isease or diabetes, but also occurred in patients with hyper-
ension and AF alone, suggests that the benefits of losartan in
atients with AF are due to prevention of vascular disease as
ell as reduced progression of established arterial disease.
Furthermore, our study does not suggest high serum
otassium as the cause of increased cardiovascular morbidity
nd mortality, because our hypertensive patients with AF
reated with losartan had a slightly higher serum potassium
evel than those treated with atenolol.
tudy limitations. The participants in the LIFE study
ere selected for hypertension and ECG LV hypertrophy
ut also for lack of current need for atenolol, losartan, or
ts with a history of atrial fibrillation for occurrence of (A) the primary
l infarction; (D) fatal or non-fatal stroke; and (E) all-cause mortality.patienngiotensin-converting enzyme inhibitors, or known intol-
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March 1, 2005:705–11 Treatment of LV Hypertrophy and AFrance to primary study treatment. Furthermore, in view of
he relatively low proportion of patients treated with non-
ihydropyridine calcium blockers, most patients in the
resent study could be rate-controlled by digoxin alone or by
o antiarrhythmic treatment during the study. However, in
iew of the large number of hypertensive patients age 55 to
0 years with LV hypertrophy meeting the LIFE study
lood pressure criteria, estimated at 3.9 million in the U.S.
nd 4.8 million in the European Union (21,22), a consid-
rable number of hypertensive patients with AF might have
heir risk of cardiovascular events and stroke reduced by
osartan therapy.
Although the analysis of AF was not pre-specified in the
IFE study analysis plan from 1995, evaluation of treatment
ffects in the subgroup of patients with AF at baseline was a
lanned secondary analysis before termination (September
001) and unblinding. Furthermore, since the sub-study pop-
lation was recruited for hypertension and ECG LV hyper-
rophy and not for AF, balanced randomization is not guar-
nteed.
Because outcomes were analyzed by the intention-to-treat
rinciple and without restriction after study drug discontinua-
ion, open-label use of angiotensin-II receptor blocker/
ngiotensin-converting enzyme inhibitor/beta-blocker may
ave diminished the difference between the groups.
onclusions. Losartan-based antihypertensive therapy was
ore effective than an atenolol-based regimen in reducing
he risk of the primary composite end point of cardiovas-
ular morbidity and cardiovascular mortality as well as the
econdary end points of stroke and cardiovascular death in
ypertensive patients with ECG LV hypertrophy and a
istory of AF. Hypertensive patients with AF who do not
eed beta-blockade for heart rate control seem to benefit
ore from losartan-based treatment than from conventional
ntihypertensive and anti-arrhythmic treatment.
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